Mexico - Delayed Quote MXN

Invitae Corporation (NVTA.MX)

6.70

0.00

(0.00%)

At close: July 23 at 2:00:00 PM CST

Labcorp Finalizes Acquisition of Select Assets of Invitae

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of its acquisition of select assets of Invitae (OTC:NVTAQ), a leading medical genetics company. Together, Labcorp and Invitae will support patients, clinicians and pharmaceutical partners across the continuum of care, including therapy development, patient diagnosis and personalized care.

PR Newswire 5 months ago

NVTAQ

LH
Labcorp Announces Winning Bid for Select Assets of Invitae

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company. Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.

PR Newswire 8 months ago

NVTAQ

LH
Invitae Publishes its Environmental, Social and Governance (ESG) Report

Invitae (OTC: NVTA), a leading medical genetics company, today published its 2024 Environmental, Social and Governance (ESG) Report. This report provides a holistic view of the company's approach to ESG and its performance and progress through measurable data and metrics during the 2023 fiscal year.

PR Newswire 8 months ago

NVTAQ
Invitae gets court approval for five-month bankruptcy sale

Invitae Corp received court approval on Thursday to run a five-month bankruptcy sale process, allowing the genetic testing company to find a buyer and exit from Chapter 11 by late July. U.S. Bankruptcy Judge Michael Kaplan approved the Softbank-backed company's proposed bid procedures at a court hearing in Trenton, New Jersey, setting an April 10 deadline for initial bids and scheduling an auction for April 17. Invitae, which filed for bankruptcy protection on Tuesday, intends to seek court approval of the sale on May 6 and expects to close the transaction by July 21.

Reuters 10 months ago

NVTA
Genetic test maker Invitae files for bankruptcy protection in US

To ensure its business operates as usual, Invitae has requested court approval to fund its bankruptcy protection by using cash on hand, the company said, adding that it intends to transition into Chapter 11 without disrupting operations. The company said in a court filing that its estimated assets were in the $500 million - $1 billion range, while its liabilities were in the $1 billion - $10 billion range. Invitae, which provides genetic testing services for various diseases and cancers in and outside the United States, added in the filing that it had around 1,000-5,000 creditors.

Reuters 10 months ago

NVTA
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process

Invitae (OTC: NVTA), a leading medical genetics company, announced today that it is building on previous actions to manage costs and improve its business structure by filing for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of New Jersey. Through this filing, the Company intends to safeguard its business, customers, patients and employees while working to execute an efficient and value-maximizing sale process with the support of its senior noteholders.

PR Newswire 10 months ago

NVTA
Invitae hires advisers, considers bankruptcy: WSJ

Sources told the Wall Street Journal a bankruptcy filing could come within weeks.

MedTech Dive 10 months ago

NVTA

FCN
SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics company, grappling with a substantial $1.5 billion debt burden, is enlisting the expertise of restructuring advisers from FTI Consulting and legal counsel from Kirkland & Ellis to navigate its financial challenges. Amidst this financial turmoil, Invitae is actively exploring various strategic options,

Benzinga 11 months ago

NVTA

SFTBY

ME
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.

PR Newswire 11 months ago

NVTA

BBIO
Is Invitae Stock a Buy Now?

Invitae shares have lost more than 80% over the past year and a half.

Motley Fool 11 months ago

NVTA
Invitae Completes Sale of Reproductive Health Assets to Natera

Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include carrier screening and non-invasive prenatal screening, to Natera (NASDAQ: NTRA).

PR Newswire 11 months ago

NTRA

NVTA
Invitae sells reproductive health assets amid liquidity concerns

DNA testing firm Natera could pay up to $52.5 million total, and plans to move Invitae’s customers to its own tests.

MedTech Dive 11 months ago

NVTA

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Invitae Corporation (NVTA.MX)

Labcorp Finalizes Acquisition of Select Assets of Invitae

Labcorp Announces Winning Bid for Select Assets of Invitae

Invitae Publishes its Environmental, Social and Governance (ESG) Report

Invitae gets court approval for five-month bankruptcy sale

Genetic test maker Invitae files for bankruptcy protection in US

Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process

Invitae hires advisers, considers bankruptcy: WSJ

SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

Is Invitae Stock a Buy Now?

Invitae Completes Sale of Reproductive Health Assets to Natera

Invitae sells reproductive health assets amid liquidity concerns